Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Akorn-Strides has announced the approvals of two abbreviated new drug applications for Ondansetron Injection USP, 4mg/2mL single dose vials and Ondansetron Injection USP, 40mg/20mL multiple dose vials.
Subscribe to our email newsletter
Ondansetron Injection is an antiemetic and is indicated for the prevention of nausea and vomiting associated with cancer chemotherapy and postoperative conditions.
Arthur Przybyl, president and CEO of Akorn, said: “We are excited to announce these two ANDA product approvals for Ondansetron Injection.”